Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the US. Food and drug administration: Empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the southern network on adverse reactions (SONAR)

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 8, 2012, Pages 905-907

  Moore, Thomas J ^a,b   Bennett, Charles L ^b,c,d,e,f  

^a INSTITUTE FOR SAFE MEDICATION PRACTICES   (United States)

^b Southern Network on Adverse Reactions (SONAR) Project   (United States)

^c South Carolina Center of Economic Excellence for Medication Safety   (United States)

^d University of South Carolina   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f WJB Dorn VA Medical Center   (United States)

Author keywords

adverse drug events; clopidogrel; hemorrhage; thalidomide; ticlopidine; U.S. Food and Drug Administration; venous thromboembolism; warfarin

Indexed keywords

CLOPIDOGREL; THALIDOMIDE; TICLOPIDINE; WARFARIN;

ADVERSE EVENT REPORTING SYSTEM; AGED; ARTICLE; BLEEDING; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HEMORRHAGE; HUMANS; THALIDOMIDE; THROMBOSIS; TICLOPIDINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WARFARIN;

EID: 84868554176     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1328890     Document Type: Article

References (14)

1. Ahmad S. R., Goetsch R. A., Marks N. M. Spontaneous reporting in the United States. In: Strom B. L., ed. Pharmacoepidemiology. 4th ed. Chichester, United Kingdom John Wiley & Sons, LTD: 2005; 135 159
2. Title 21 314.80 Postmarketing reporting of adverse drug experiences. United States Code of Federal Regulations. 2011. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.80. Accessed May 3, 2012
3. Moore T. J., Cohen M. R., Furberg C. D. Signals for two newly approved drugs and 2010 annual summary. QuarterWatch: monitoring MedWatch reports. 2012. Available at: http://www.ismp.org/QuarterWatch/pdfs/2010Q4.pdf. Accessed May 3, 2012
4. U.S. Food and Drug Administration. Reports Received and Reports Entered into AERS By Year. 2011. Available at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ ucm070434.htm. Accessed May 3, 2012
5. Kessler D. A. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA: 1993; 269 21 2765 2768 (Pubitemid 23154251)
6. Warren J. L., McBean A. M., Hass S. L., Babish J. D. Hospitalizations with adverse events caused by digitalis therapy among elderly Medicare beneficiaries. Arch Intern Med: 1994; 154 13 1482 1487 (Pubitemid 24208573)
7. McAdams M., Staffa J., Dal Pan G. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf: 2008; 17 3 229 239 (Pubitemid 351404034)
8. Lazarou J., Pomeranz B. H., Corey P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA: 1998; 279 15 1200 1205 (Pubitemid 28193431)
9. Budnitz D. S., Lovegrove M. C., Shehab N., Richards C. L. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med: 2011; 365 21 2002 2012
10. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
11. Moore T. J., Cohen M. R., Furberg C. D. Signals for Fingolimod (GILENYA) and Infliximab (REMICADE). Institute for Safe Medication Practices QuarterWatch: monitoring FDA MedWatch reports. 2012. Available at: http://www.ismp.org/ QuarterWatch/pdfs/2011Q2.pdf. Accessed April 12, 2012.
12. MedDRA Maintenance and Support Services Organization Introductory guide to standardised MedDRA queries (SMQs) Version 14.1. Chantilly, VA MedDRA Maintenance and Support Services Organization: 2011
13. Bennett C. L., Angelotta C., Yarnold P. R., et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA: 2006; 296 21 2558 2560 (Pubitemid 44903859)
14. Chen B., Restaino J. R., Sartor A. O., et al. A state attorney general and a hematologist facilitate translation of research into US Food and Drug Administration actionsa SONAR report. J Oncol Pract: 2012; 10.1200/JOP.2011. 000504